T
HE LIVER is particularly prone to excessive hemorrhage as a result of abdominal trauma or during elective hepatic resection. 1, 2 The predisposition of this organ to diffuse bleeding is directly related to its extreme vascularity, particularly because of the hepatic sinusoidal structure, which does not have smooth muscle capable of contraction to induce vasoconstriction. 3 Consequently, traumatic damage, including parenchymal lacerations and fractures, and surgical cutting during elective operative procedures (eg, tumor resection) tend to expose wide, raw surfaces with multiple bleeding sites that are often not amenable to suturing and ligation. 2, 4, 5 In the case of trauma, underlying coagulopathy may further complicate the effective control of diffuse bleeding, and this sometimes requires that measures such as perihepatic packing be undertaken. [5] [6] [7] Effective hemostasis during hepatic resection also can be difficult to attain and is especially troublesome in the cirrhotic patient. In these patients, marked h e m o r r h a g i c d i a t h e s e s a r e o f t e n observed, which may make intraopera-
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tive bleeding difficult to control and also increase the likelihood of postsurgical rebleeding. 8 A number of hemostatic methods have been evaluated as adjunctive procedures in hepatic resection. 9 Manual compression and packing of the raw liver surfaces to tamponade bleeding sites are commonly performed with the use of gauze, sponges, and other agents. 6, [10] [11] [12] Topical hemostatic agents also have been used with varying degrees of success in this setting. These agents include oxidized regenerated cellulose, 13 
PATIENTS AND METHODS

SUBJECT SAMPLING
Data were gathered during a multicenter, randomized controlled trial in 4 distinct surgical indications: general, hepatic, cardiac, and orthopedic. This larger study was conducted at 10 geographically dispersed US medical centers to determine the safety and effectiveness of a novel collagenbased composite compared with standard methods of hemostasis for control of diffuse bleeding under an investigational device exemption (IDE). To qualify for inclusion in this clinical investigation, all male and nonpregnant female patients provided informed consent, supplied a medical history, and reported no history of sensitivity to bovine thrombin or collagen, or anaphylaxis from any cause. Overall, 318 patients were entered into the study and received study-specific hemostasis.
RANDOMIZATION PROCEDURES
Randomization was stratified within each clinical site and within each surgical indication. Thus, separate computergenerated randomization schedules of treatment group assignment placed in sealed envelopes were used for each clinical site and for each type of surgery. The hepatic surgical group consisted of 80 adult patients scheduled for hemihepatectomy or segmental resection of the liver by tangential excision. These patients were recruited from 7 of the 10 participating clinical centers and randomly assigned on a one-to-one basis in blocks of 6 to either treatment (45 patients) or control (35 patients). The slight imbalance in sample size between the 2 treatment groups resulted from several clinical centers contributing small numbers of patients to the study, leading to randomization within incomplete blocks. Patients suspected of having, or diagnosed as having, liver abscesses were ineligible for inclusion in this surgical subgroup. Figure 1 illustrates the randomization procedure and patient throughput in addition to the specific reason(s) for excluding patients from the analyses of hemostatic effectiveness. Briefly, 6 patients in each study group never received study-specific hemostasis and 1 additional patient in the experimental group was concurrently treated with an absorbable gelatin sponge. Consequently, 67 patients (38 in the treatment group and 29 in the control group) participated as study subjects and provided complete data with respect to the time required to achieve controlled bleeding and complete hemostasis (Figure 1 ).
HEMOSTATIC INTERVENTIONS
The objective of this multicenter, randomized controlled trial was to determine the safety and effectiveness of a novel collagen-based composite combined with autologous plasma compared with a standard method of hemostasis for control of diffuse bleeding during hepatic surgery. The experimental hemostatic agent, CoStasis Surgical Hemostat (Cohesion Technologies Inc, Palo Alto, Calif), is a composite of bovine microfibrillar collagen and bovine thrombin that is mixed with autologous plasma at the time of surgery and is composed of a sterile suspension of bovine fibrillar collagen (20 mg/mL) and bovine thrombin (500 U/mL) in a calcium chloride buffer (40 mmol/L). The premixed collagen-thrombin suspension is supplied in one syringe and is mixed intraoperatively with an equal volume of the subject's own plasma from a second syringe. The subject's plasma provides the fibrinogen that is cleaved by the thrombin to form a collagen-fibrin gel matrix. This composite was applied without pressure (tamponade) to the bleeding surface(s) in all subjects assigned to the experimental group. All control subjects had bleeding of the liver parenchyma and/or associated lobar tissue managed with absorbable collagen sponges (Instat; Johnson & Johnson, New Brunswick, NJ) applied with manual pressure by the surgeon.
OUTCOMES
The duration of bleeding from the raw surface of the liver at the completion of parenchymal transection was recorded with a stopwatch by a trained study coordinator, starting at the time that the hemostatic intervention was initiated. If hemostasis had not occurred within 10 minutes, the intervention was recorded as a treatment failure. Two hemostasis points were recorded for the purposes of evaluating effectiveness. The time to controlled bleeding was defined as the time elapsed from the initial application of the treatment or control intervention until the bleeding from the exposed surfaces had slowed to a slight oozing. The time to complete hemostasis was defined as the time elapsed from the initial application of the treatment or control intervention until the investigator indicated that bleeding from the exposed surfaces had stopped completely. If a subject's bleeding stopped completely without passing through a controlled bleeding phase, the time to controlled bleeding was set equal to the time to complete hemostasis.
STATISTICAL METHODS
The primary effectiveness end point, hemostatic success, was defined a priori as the cumulative rate for each treatment group to achieve complete hemostasis within 10 minutes of observation. These hemostatic success rates were compared between experimental and control subjects by means of Fisher exact test. The time to controlled bleeding and the time to complete hemostasis were evaluated for each treatment group by means of the Kaplan-Meier estimation. The cumulative complete hemostasis rates are displayed graphically in Figure 2 for the 2 groups, and these distributions were compared statistically by means of the log rank test. All time-to-event data are presented as median (± SE) values and are censored at 10 minutes. absorbable gelatin sponge with and without thrombin, 14 microfibrillar collagen, 9,15 fibrin sealants commonly produced with components from pooled human blood, [16] [17] [18] [19] [20] and various composites of these materials. 21, 22 The current randomized controlled trial evaluated the hemostatic performance of a novel collagen-based composite combined with autologous plasma (experimental group) compared with a collagen sponge with manual compression (control group). The comparative effectiveness of these approaches was determined at raw, diffusely bleeding liver sites exposed by surgical resection, mainly among patients undergoing elective tumor resection.
RESULTS
The median age for all subjects in the hepatic group was 58 years (range, 21-88 years), and this group consisted of 29 men (43%) and 38 women (57%). There were no statistically significant differences between the experimental and control groups with respect to age or sex.
Twenty-five subjects underwent surgery to remove a primary cancer (hepatocellular carcinoma), 36 subjects had removal of liver metastases (mainly of colorectal origin), 2 subjects had surgical correction of traumainduced injuries, and 4 subjects had other types of problems requiring liver resection.
The proportion of subjects achieving complete hemostasis within the 10-minute period of observation (ie, hemostatic success) is presented in the Table. All 38 experimental group subjects (100%) achieved complete hemostasis within 10 minutes. By contrast, less than 70% (20/29) of control subjects achieved complete hemostasis during the same duration of observation. These hemostatic success rates (ie, 38/38 vs 20/29) were significantly different (PϽ.001) (Table) .
The Table also shows the median times to controlled bleeding and complete hemostasis. There was an approximately 4-fold improvement in the median time to controlled bleeding among experimental group subjects (62 seconds) compared with control subjects (250 seconds), and this difference was highly significant (PϽ.001) (Table) . The time to complete hemostasis in the experimental group was less than half that in the control group (150 vs 360 seconds; PϽ.001) (Table) . The comparative cumulative success rates representing the time to complete hemostasis are displayed in Figure 2 , demonstrating a striking difference in the percentage of subjects achieving complete hemostasis soon after initiation of hemostatic treatment. For instance, even after as little as 3 minutes of observation, more than half of subjects in the experimental group had stopped bleeding, whereas only about 10% of controls had achieved complete hemostasis (Figure 2) .
Of the 7 clinical centers that contributed subjects to the hepatic group, 3 centers provided more than 80% (55/67) of the patients. There were no noteworthy or statistically significant treatment group differences among these 3 centers with respect to important baseline characteristics or hemostatic effectiveness †Significance levels computed with Fisher exact test for hemostatic success rates. Time-to-event data are presented as median ± SE and significance levels are computed with the log rank test.
outcomes. Overall, there also were no differences between treatment and control subjects regarding the transfusion of whole blood, packed cells, platelets, or plasma. Similarly, there were no differences between treatment and control subjects for change from baseline values for hemoglobin, hematocrit, or plasma fibrinogen levels. There also were no adverse events, including documented episodes of rebleeding, related to the use of the investigational hemostatic agent in this study. Two deaths occurred during 8 weeks of postoperative follow-up. Both of these were in control subjects, and neither death was considered to be related to the use of the collagen sponge. Comprehensive serology panels and antibody titers were performed before and after treatment. The results of this evaluation are being submitted for publication elsewhere.
COMMENT
Few controlled trials have been conducted to determine the comparative effectiveness of hemostatic agents in the control of hepatic bleeding and, thus, treatment is often based on surgeon preference. The findings of this randomized controlled trial demonstrate the advantages of the investigational collagenbased composite over a standard method of hemostasis, collagen sponges applied with manual pressure. Indeed, there were uniform and statistically significant differences between groups favoring the experimental group with respect to the proportion of subjects achieving complete hemostasis as well as the time to controlled bleeding and the time to complete hemostasis. In addition, the effectiveness demonstrated in the experimental group was realized in the absence of concurrent tamponade, which is often required with other collagen-and thrombin-based agents. The findings of the current study also compare favorably with results reported by Kohno et al 23 of a randomized trial of microcrystalline collagen powder and fibrin glue in patients undergoing elective hepatic resection. Approximately 87% and 81% of patients treated with collagen powder and fibrin glue, respectively, achieved complete hemostasis in that study.
The analytical methods used to evaluate the results of this study included subjects who actually received protocol-specific treatment (ie, n = 67) (Figure 1) . Nonetheless, even if all excluded subjects were counted in a formal intention-to-treat analysis of hemostatic success and coded as treatment failures, the results continued to favor the experimental group at a highly significant level (38/45 vs 20/35; P = .01). Unfortunately, the participating surgeons in this study could not be blinded intraoperatively to treatment assignment, allowing for possible bias of results. However, the superior hemostatic effectiveness of the investigational hemostatic agent was observed consistently across all 7 clinical centers. In addition, the duration of bleeding was monitored and recorded by an independent study coordinator, which provided an extra level of verification to the data collection process and likely reduced any potential investigator bias.
The majority of patients in this study underwent elective hepatic resection of benign and malignant tumors. This setting provided a controlled clinical model to evaluate the hemostatic effectiveness where the liver had been surgically exposed and bleeding emanated from a wide, raw surface. Bleeding in these patients can be difficult to manage in a consistent and timely fashion, and it can be particularly troublesome in cirrhotic individuals with marked hemorrhagic diatheses. 8 It is unclear whether these encouraging findings can be extrapolated directly to the treatment of the patient with liver trauma, as few subjects with trauma-induced bleeding were included in the current study. However, similar operative procedures (eg, hemihepatectomy, wedge resection) are used occasionally to treat complex traumatic injuries to the liver, 24 and one grade IV liver laceration included in the current investigation was treated effectively with the investigational treatment. Although this novel collagen-based composite is not envisioned to supplant ligation and/or surgical repair of major vascular disruption in the traumatized liver, its adjunctive use may be helpful to control diffuse raw-surface bleeding that often accompanies these operative procedures. 4 Bleeding from experimental liver injuries in animal models has been reported to be effectively controlled with collagen-based hemostatic agents. 13, 15, 21, 22, 25 Laboratory investigations confirm that these collagenbased agents trigger platelet aggregation when directly applied to bleeding tissue. 26, 27 Bovine thrombin likewise has inherent hemostatic properties via the conversion of fibrinogen to fibrin. 22 CoStasis combines both of these materials with the patient's own plasma to form an effective, biocompatible composite in a liquid form. Importantly, obtaining the fibrinogen component from autologous plasma effectively eliminates concerns about disease transmission, commonly cited as a shortcoming of some commercial fibrin products produced from pooled human blood sources. 17 Several collagen-based hemostatic products exist that include powders, fleeces, and lyophilized sponges. These products have somewhat unsatisfactory handling properties, and their use often requires concurrent manual tamponade. 9, 28, 29 The sprayable characteristic of the investigational hemostatic agent offers potential advantages in the operative setting because wide surfaces can be treated instantaneously without the need for tamponade. Although such use was not evaluated in this study, the liquid consistency may make this investigational hemostatic agent suitable for use in minimally invasive laparoscopic procedures.
In summary, the results of this randomized controlled trial demonstrate improved hemostatic performance with CoStasis Surgical Hemostat compared with a collagen sponge in controlling diffuse hepatic bleeding among patients undergoing liver surgery. These clinical findings support consideration of the use of this investigational hemostatic agent to provide effective and timely hemostasis, especially among patients undergoing elective liver resection. 
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